The results you allude to are part of the Phase IIa trial which are limited to a 1 hour IV infusion, designed to show safety and tolerability at that dose level. Full efficacy is not quite the aim - yet, but it is reasonable to expect it to come in due course. The expected efficacy against all ESKAPE pathogens level is thought to be 500-1000ug/ml, which presumably would be achieved at 1 hour dose level of 14,000mg. That is only just over a doubling of the current level. One could assume that prolonging the 6000mg IV beyond 1 hour could also increase the peak plasma level somewhat, but the trial did not aim to do that. Increasing the dose level to 14,000mg would also be likely to deliver the required improvement in efficacy. You are welcome to your own opinion of course, but I do not think the data to date justifies concluding that RCE 327 will not "... end up being capable of treating bacteraemia/sepsis..."
RCE Price at posting:
69.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)